Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Corcept Therapeutics Inc

NASDAQ: CORT · Life Sciences · 13 alerts · CIK 1088856

Share price
$69.22Close, Nov 16
Market cap
$7.58B
Shares outstanding
109.44MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Corcept Therapeutics Inc filings on SEC EDGAR ↗

4:31 PM ET Form 4
Insider Selling

Corcept Therapeutics Director Daniel N. Swisher Jr. Sells $111K of Stock

Daniel N. Swisher Jr., Director, sold 1,500 shares of Corcept Therapeutics Inc at $74.07 a share, worth $111K in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).

Value
$111K
Shares
1,500
Price
$74.07
Role
Director
Holding change
-100.0%
Trade date
Nov 10, 2026
7:27 PM ET Form 4
Insider Selling

Corcept Therapeutics Insider Sean Maduck Sells $2.05M of Stock

Sean Maduck sold 25,000 shares of Corcept Therapeutics Inc at $81.42 to $82.68 a share (average $81.85) in 3 transactions, worth $2.05M in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 9,938 (-31.4%).

Value
$2.05M
Shares
25,000
Average price
$81.85
Holding change
-31.4%
Trade date
Nov 2, 2026 to Nov 3, 2026
7:21 PM ET Form 4
Insider Selling

Corcept Therapeutics President, Oncology Roberto Wandenkolk Vieira Sells $674K of Stock

Roberto Wandenkolk Vieira, President, Oncology, sold 8,333 shares of Corcept Therapeutics Inc at $80.73 to $81.52 a share (average $80.89) in 2 transactions, worth $674K in total on Nov 2, 2026. Shares held after the trade: 3,946 (-29.8%).

Value
$674K
Shares
8,333
Average price
$80.89
Role
President, Oncology
Holding change
-29.8%
Trade date
Nov 2, 2026
4:12 PM ET 10-Q
Financial Results

Corcept Therapeutics Q3 2026 Results: Net Income $127M, Up 544.6% YoY

Corcept Therapeutics reported a significant increase in net income to $126.8 million for the third quarter of 2026, compared to $19.7 million in the prior year, driven by a 64% increase in product revenue. The company maintained a strong balance sheet with over $1 billion in total assets and continued its stock repurchase program, though it recorded a net loss in the first quarter of the year.

Key figure
Net income $127M · +544.6% YoY
4:09 PM ET 8-K
Financial Results

Corcept Therapeutics Financial Results

Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, a 64% increase year-over-year, driven by strong growth in Korlym and the rapid uptake of Lifyorli in ovarian cancer. Net income rose significantly to $126.8 million, or $1.01 per diluted share, while the company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.

Term
Q3 2026

“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business. Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.”

Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer

“The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome. Optimal care starts with screening and a correct diagnosis. The ADA/EASD report also identifies mifepristone as a potential treatment, citing the positive results of our CATALYST trial.”

Bill Guyer, PharmD, Corcept’s Chief Development Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.